PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMelarsoprol
Melarsoprol
Melarsoprol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01C: Agents against leishmaniasis and trypanosomiasis
— P01CD: Arsenic compounds, for leishmaniasis and trypanosomiasis
— P01CD01: Melarsoprol
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Traumatic brain injuriesD000070642—S06———1—1
DepressionD003863—F33.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.0—21——3
Immunoglobulin light-chain amyloidosisD000075363————1——1
African trypanosomiasisD014353—B56——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.932———3
NeoplasmsD009369—C8031———3
Hematologic neoplasmsD019337———2———2
Breast neoplasmsD001943EFO_0003869C50—1———1
Myeloid leukemia acuteD015470—C92.0—1———1
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0—1———1
Residual neoplasmD018365———1———1
Myelomonocytic leukemia juvenileD054429—C93.3—1———1
Neurofibromatosis 1D009456—Q85.01—1———1
Chromosome aberrationsD002869Orphanet_68335——1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C951————1
Myelodysplastic syndromesD009190—D461————1
Myeloproliferative disordersD009196—D47.11————1
Plasma cell neoplasmsD054219——1————1
Dental plaqueD003773——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic brain diseasesD001928—G93.41————11
Physiological stressD013312——————11
Chronic periodontitisD055113EFO_0006343K05.3————11
Periodontal diseasesD010510—K05.6————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMelarsoprol
INNmelarsoprol
Description
Melarsoprol is a member of triazines.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(N)nc(Nc2ccc([As]3SCC(CO)S3)cc2)n1
Identifiers
PDB—
CAS-ID494-79-1
RxCUI—
ChEMBL IDCHEMBL166
ChEBI ID6729
PubChem CID10311
DrugBank—
UNII IDZF3786Q2E8 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,657 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use